KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Net Income: 2020-2023

Historic Net Income for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -$47.1 million.

  • AbCellera Biologics' Net Income fell 57.73% to -$47.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 192.35%. This contributed to the annual value of -$162.9 million for FY2024, which is 11.24% down from last year.
  • According to the latest figures from Q4 2023, AbCellera Biologics' Net Income is -$47.1 million, which was down 64.80% from -$28.6 million recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' Net Income ranged from a high of $168.6 million in Q1 2022 and a low of -$47.1 million during Q4 2023.
  • Moreover, its 3-year median value for Net Income was -$14.1 million (2021), whereas its average is $13.8 million.
  • Examining YoY changes over the last 5 years, AbCellera Biologics' Net Income showed a top increase of 5,700.62% in 2021 and a maximum decrease of 693.91% in 2021.
  • Quarterly analysis of 4 years shows AbCellera Biologics' Net Income stood at $161.2 million in 2020, then crashed by 62.80% to $59.9 million in 2021, then plummeted by 149.86% to -$29.9 million in 2022, then plummeted by 57.73% to -$47.1 million in 2023.
  • Its Net Income was -$47.1 million in Q4 2023, compared to -$28.6 million in Q3 2023 and -$30.5 million in Q2 2023.